PRESS RELEASES
March 3, 2022 -- NephroSant Publishes Real-World Evidence Showing Potential to Improve the Detection of Early Kidney-Transplant Rejection Events
February 28, 2022 -- The DirectWomen Board Institute names Michele Colucci to 2022 Institute Class
December 15, 2021 -- Delphi Diagnostics announces breakthrough research information
October 28, 2021 -- Optina Diagnostics closes an oversubscribed Series-A Round of CA$24.8 million, with an additional $2.1m Note on the heels of this from the Alzheimer’s Dementia Discovery Fund
September 22, 2021 -- NephroSant Secures Medicare Coverage for QSant, the First Urine-based Kidney Transplant Rejection Test, and Plans 2022 Launch
February 28, 2022 -- The DirectWomen Board Institute names Michele Colucci to 2022 Institute Class
December 15, 2021 -- Delphi Diagnostics announces breakthrough research information
October 28, 2021 -- Optina Diagnostics closes an oversubscribed Series-A Round of CA$24.8 million, with an additional $2.1m Note on the heels of this from the Alzheimer’s Dementia Discovery Fund
September 22, 2021 -- NephroSant Secures Medicare Coverage for QSant, the First Urine-based Kidney Transplant Rejection Test, and Plans 2022 Launch
